Nav: Home

Novel mechanism in drug combination shows potential for treating leukemia, other cancers

October 10, 2016

Researchers have discovered a novel mechanism in a combination drug therapy that shows potential as a new approach for treating acute myeloid leukemia (AML) and many other cancers. When combined, these agents cause interactions that significantly disrupt cancer cells' ability to survive DNA damage, according to a preclinical study published today in the journal Cancer Cell.

The study looked at a combination of two drugs, both of which significantly reduce some cancer cells' ability to survive and propagate. One was a DNA methyltransferase (DNMT) inhibitor, while the other was a poly-ADP-ribose polymerase (PARP) inhibitor, talazoparib. PARP inhibitors target and block proteins which cancer cells depend on to repair DNA for their survival. DMNT inhibitors, such as 5-azacytidine and decitabine, boost the interactions of PARP inhibitors to block these proteins even further, causing cancer cell death, the researchers found.

"Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML," says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

"Moreover, our initial data suggest that subtypes of AML with a poor prognosis are likely to be sensitive to this new therapeutic approach," she says, adding that less than 10 percent of patients with certain forms of AML achieve long-term survival.

A blood cancer characterized by the rapid growth of abnormal white blood cells, AML is typically treated with chemotherapy, in some cases followed by a stem cell transplant. DNMT inhibitors are frequently used to treat patients unlikely to respond to chemotherapy or who have not responded to chemotherapy.

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who cannot receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment. The trial, which will be led by Maria R. Baer, MD, professor of medicine at UM SOM and director of hematologic malignancies at UMGCCC, will enroll patients at the Greenebaum Comprehensive Cancer Center and several other sites.

"This is really a new paradigm mechanism that is being translated into a clinical trial," Dr. Rassool says. "It's not just putting two drugs together. We have shown in the laboratory that the proteins that these inhibitors target actually interact, so the effects of these inhibitors are enhanced through this interaction. Therein lies the novelty of this new approach."

The research, conducted in cell lines and mouse models, explored enhancing the cancer-killing effects of PARP inhibitors not only in regard to AML but also triple-negative breast cancer. PARP inhibitors have shown efficacy for a small group of patients with breast cancer with inherited mutations in BRCA genes, but have failed in the more aggressive triple-negative disease. "Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers," Dr. Rassool says.

Dr. Rassool and colleagues at UMGCCC and UMSOM collaborated with scientists at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the National Institute on Aging. Stephen B. Baylin, MD, the Virginia and DK Ludwig Professor of Oncology and Medicine and associate director for research programs at the Johns Hopkins Kimmel Cancer Center, is the study's co-senior author.

The research, which builds on previous work by Dr. Rassool and Dr. Baylin, was funded by a number of grants, including Stand Up To Cancer's inaugural Laura Ziskin Prize in Translational Research - a $250,000 grant awarded to the two researchers in 2012. Ziskin, a Hollywood film producer who died of metastatic breast cancer, was a co-founder of Stand Up To Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as possible.

PARP inhibitors are used primarily to treat tumors linked to defects in BRCA genes, but may show promise in other cancers when combined with other drugs. Certain kinds of cancer cells depend heavily on PARP to repair DNA damage. If PARP is blocked, these cells die. PARP inhibitors also cause PARP to become trapped in the cancer cells' DNA, a process that is greatly enhanced when a DMNT inhibitor is added, Dr. Rassool says. This leads to massive DNA damage that cannot be repaired, and the cancer cells self-destruct.

DNMT inhibitors suppress DNA methylation, resulting in gene expression that significantly interferes with cancer cell growth. They are not usually combined with PARP inhibitors.

"Dr. Rassool and her colleagues have identified an exciting new mechanism for attacking cancer that may ultimately provide a new option for treating patients with leukemia and other cancers," says E. Albert Reece, MD, PhD, MBA, vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of UMSOM. "We are committed to translational research, and this is excellent example of how we are able to move an important scientific discovery in the laboratory into the clinic where it may potentially benefit patients."
-end-
In addition to the Ziskin Prize, support for the research came from the Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team, the Adelson Medical Research Foundation, the Maryland Cigarette Restitution Fund Program, the Leukemia & Lymphoma Society, and the Intramural Research Program of the National Institute on Aging.

About the University of Marlene and Stewart Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of Medicine. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked in the top 25 cancer programs in the nation by U.S. News & World Report. http://www.umgccc.org.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States. It continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland's Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world. http://www.medschool.umaryland.edu.

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer

Nidal Muvarak, Khadiza Chowdhury, Limin Xia, Carine Robert, Eun Yong Cho, Yi Cai, Marina Bellani, Ying Zou, Zeba N. Singh , Vu H. Duong, Tyler Rutherford, Pratik Nagaria, Søren M. Bentzen, Michael M. Seidman, Maria R. Baer, Rena G. Lapidus, Stephen B. Baylin, Feyruz V. Rassool

University of Maryland School of Medicine

Related Breast Cancer Articles:

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.